ID   ICC5
AC   CVCL_VV28
DR   cancercelllines; CVCL_VV28
DR   Cell_Model_Passport; SIDM01803
DR   DepMap; ACH-001845
DR   Wikidata; Q94313317
RX   PubMed=27231123;
RX   PubMed=35640676;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 5 days (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Val (c.394_395CG>GT); Zygosity=Unspecified (PubMed=27231123; DepMap=ACH-001845).
CC   Miscellaneous: Doubling time and age/sex of donor from personal communication of El-Bardeesy, Nabeel.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap=ACH-001845
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,14
ST   D16S539: 13
ST   D18S51: 15,17
ST   D21S11: 28,32.2
ST   D3S1358: 14
ST   D5S818: 12,13
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 23,25
ST   Penta D: 10,11
ST   Penta E: 9,11
ST   TH01: 9,10
ST   TPOX: 8
ST   vWA: 21
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 12
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.M.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//